Sleep & Recovery Stack

The Sleep & Recovery Stack combines three peptides that target distinct biological pathways involved in sleep regulation. Epitalon — a synthetic tetrapeptide derived from the pineal gland — research suggests may restore age-related decline in melatonin secretion through direct interaction with MT1 receptors [PMID: 10709557]. Selank, a tuftsin-derived heptapeptide, studies indicate may reduce anxiety and neuroinflammation through GABAergic modulation and enkephalinase inhibition, addressing a primary cause of sleep-onset difficulty [PMID: 21833148]. Sermorelin, a synthetic GHRH analog, research suggests may enhance deep slow-wave sleep by amplifying endogenous growth hormone pulsatility during the first sleep cycle [PMID: 18031173].

What makes this combination particularly interesting to researchers is that each peptide appears to address a different dimension of sleep dysfunction. Epitalon targets the circadian signaling layer — the pineal-melatonin axis that governs sleep-wake timing. Selank addresses the arousal and anxiety layer — the neuroinflammatory and GABAergic tone that determines sleep-onset latency. Sermorelin operates at the sleep architecture layer — the GH-dependent slow-wave consolidation that defines sleep depth and restorative quality. This multi-level approach leads researchers to hypothesize that the three compounds may produce complementary rather than redundant effects.

All three compounds are classified as research peptides. Epitalon evidence derives primarily from preclinical animal models and small Russian clinical trials. Selank has been studied in controlled clinical settings for generalized anxiety disorder. Sermorelin carries the most extensive clinical data as a former FDA-approved diagnostic agent. No human clinical trial has established efficacy or safety for this specific combination. The information on this page reflects the published scientific literature as a resource for researchers — not guidance for human use, medical treatment, or diagnosis.

The scientific rationale for this three-compound stack rests on targeting three distinct layers of sleep regulation that are often disrupted simultaneously in age-related sleep deterioration.

Epitalon operates at the level of the pineal-melatonin axis. Research indicates it may directly influence melatonin synthesis by interacting with MT1 receptors in the pineal gland [PMID: 10709557]. Studies also suggest it may restore age-related decline in pineal gland function, which is a primary contributor to circadian rhythm disruption in older adults [PMID: 15865243]. Additionally, epitalon has been studied for its role in telomerase activation, which may support cellular longevity in pinealocytes — the cells responsible for melatonin production [PMID: 12398480].

Selank addresses the neurochemical barrier to sleep onset. Research suggests it may inhibit enkephalinase, an enzyme that breaks down endogenous opioid peptides, potentially enhancing the body's natural calming mechanisms [PMID: 21833148]. Studies also indicate it modulates pro-inflammatory cytokines — specifically IL-6 and TNF-alpha — which are known to impair sleep quality when chronically elevated [PMID: 21493795]. Its interaction with the GABAergic system is believed to produce anxiolytic effects that may reduce the hyperarousal state responsible for sleep-onset insomnia [PMID: 21833148].

Sermorelin targets the growth hormone-sleep architecture feedback loop. The endogenous GH axis exhibits pronounced sleep-dependent pulsatility: the largest GH pulse of the 24-hour period reliably occurs within the first 90 minutes of sleep onset, coinciding with the first slow-wave sleep episode [PMID: 18031173]. Research in aged animal models demonstrates that somatopause — the age-associated decline in GH/IGF-1 — is characterized by both reduced slow-wave sleep delta power and blunted nocturnal GH pulsatility, suggesting a causal bidirectional relationship [PMID: 9141536]. Sermorelin, as a GHRH analog, may help restore this coupling.

The complementarity here is mechanistically compelling. Epitalon may restore the circadian signal that initiates sleep. Selank may remove the neurochemical obstacles that delay sleep onset. Sermorelin may enhance the sleep architecture that determines restorative quality. Because these targets appear largely non-overlapping, researchers hypothesize that the combination may address multiple dimensions of age-related sleep dysfunction simultaneously.

No clinical trial has tested this specific three-compound combination in humans. The synergy rationale is extrapolated from independent studies on each compound. Researchers should treat the evidence as exploratory.

A notable feature of this stack is that the three peptides use different administration routes, which complicates but does not preclude combined protocol design. Epitalon is typically studied via subcutaneous injection at doses of 5–10 mg/day in short 10-day cycles [PMID: 15865243]. Selank is commonly administered intranasally at 0.15–0.3 mg/day [PMID: 21493795]. Sermorelin is administered subcutaneously, typically at 0.2–0.3 mg (200–300 mcg) at bedtime [PMID: 9141536].

The timing of administration is particularly relevant for this stack. Sermorelin is most commonly studied when administered at bedtime, aligning with the natural nocturnal GH pulse. Epitalon's influence on melatonin secretion suggests evening administration may be most relevant to circadian rhythm research. Selank's short half-life and anxiolytic properties make it suitable for administration in the period before intended sleep onset.

The three compounds differ significantly in their studied dosing patterns and cycle durations. Epitalon research protocols typically involve short intensive cycles of 10 days, reflecting the cumulative nature of its effects on pineal function. Selank clinical studies have examined continuous daily administration over periods of weeks. Sermorelin research protocols commonly involve longer durations of daily administration, reflecting the time required for measurable changes in GH axis function.

No standardized combined protocol exists for this three-compound stack. All available information reflects independent studies on each compound, anecdotal research use, or extrapolation from related peptide combinations. Researchers should maintain careful documentation of any combined protocol, including timing, doses, and observed effects on sleep quality metrics.